Get the Stockscreener App
1.05
0.94%
-0.01
After Hours:
1.03
-0.02
-1.90%
Oncolytics Biotech Inc stock is traded at $1.05, with a volume of 1.00M.
It is down -0.94% in the last 24 hours and up +25.51% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$1.06
Open:
$1.06
24h Volume:
1.00M
Relative Volume:
0.80
Market Cap:
$112.99M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.9698
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-1.87%
1M Performance:
+25.51%
6M Performance:
-0.94%
1Y Performance:
+42.30%
1-Day Range:
$1.03
$1.08
1-Week Range:
$0.9801
$1.15
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.05 | 114.06M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types - Newswire Canada
Cancer Treatment Breakthroughs Stack Up as Clinical Pipelines Advance - Baystreet.ca
Earnings Report: Is Oncolytics Biotech Inc undervalued by DCF analysisJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion - Cantech Letter
Oncolytics Biotech Launches Randomized Phase 2 REO-033 Trial for Pelareorep in RAS-Mutant MSS Metastatic Colorectal Cancer — With FDA Fast Track Behind It - Oncodaily
Oncolytics launches phase 2 colorectal cancer study REO 033 - Investing.com
Oncolytics Biotech Launches Phase 2 Colorectal Cancer Trial - TipRanks
Oncolytics Biotech Launches Randomized Colorectal Cancer Study - Bitget
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech (NASDAQ: ONCY) launches Phase 2 pelareorep colorectal cancer study - Stock Titan
Oncolytics Biotech Inc initiates phase 2 study for metastatic colorectal cancer - marketscreener.com
Oncolytics (ONCY) Initiates Phase 2 Trial for Metastatic Colorec - GuruFocus
Oncolytics Biotech IncInitiates Phase 2 Study For Metastatic Colorectal Cancer - TradingView
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study - The Manila Times
Oncolytics launches phase 2 colorectal cancer study REO 033 By Investing.com - Investing.com UK
Colorectal cancer trial to test new immunotherapy after chemo fails - Stock Titan
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Enrollment Milestone - Sahm
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Milestone - Sahm
Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday - MarketBeat
Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView
Lake Street Sticks to Their Buy Rating for Oncolytics Biotech (ONCY) - The Globe and Mail
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude - MSN
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 - Cantech Letter
Oncolytics to wind down GOBLET study, focus on U.S. registration - Investing.com India
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge - The Malaysian Reserve
Death Cross: Will Oncolytics Biotech Inc outperform the market in YEARJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Foc - GuruFocus
Oncolytics to wind down GOBLET study, focus on U.S. registration By Investing.com - Investing.com Canada
Oncolytics to stop enrollments for GIT cancer trial (ONCY) - Seeking Alpha
Oncology Market Set to Nearly Triple: Here Are Five Companies Le - GuruFocus
Oncolytics (ONCY) Completes Enrollment in GOBLET Study, Advances Cancer Research - GuruFocus
Cancer Drug Market on Track to Double by 2033: Five Oncology Plays to Watch - Baystreet.ca
Oncolytics Refocuses Pipeline on Key GI Cancer Programs - TipRanks
Oncolytics Biotech (ONCY) pivots to registration-focused anal and colorectal cancer trials - Stock Titan
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer - ChartMill
Can Oncolytics Biotech Inc expand its profit marginsQuarterly Profit Summary & Growth Focused Stock Reports - baoquankhu1.vn
Trading Recap: How sensitive is Oncolytics Biotech Inc to inflationWeekly Loss Report & Verified Trade Idea Suggestions - baoquankhu1.vn
Risk Off: Is Oncolytics Biotech Inc undervalued by DCF analysis2025 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn
What are Oncolytics Biotech Inc.’s earnings expectationsPortfolio Performance Summary & Low Risk High Reward Ideas - mfd.ru
Patterns Watch: How is Oncolytics Biotech Inc managing supply chain issuesJuly 2025 PreEarnings & Community Consensus Trade Signals - baoquankhu1.vn
Aug Spikes: Can Oncolytics Biotech Inc expand its profit marginsMarket Trend Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Big Money Moves: What drives CRWDs stock price2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
THE INFRASTRUCTURE REALIGNMENT: 5 Stocks Positioning for the 2026 Supply Imperative - The Globe and Mail
Smart Money: What is Oncolytics Biotech Incs 5 year growth outlookMarket Movers & Community Verified Trade Signals - baoquankhu1.vn
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
Public market insider buying at Oncolytics Biotech (ONC) - The Globe and Mail
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else - PR Newswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else - Benzinga
Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep - Yahoo Finance
Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer - Yahoo Finance
Oncolytics Biotech Inc. (NASDAQ:ONCY) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Oncolytics Biotech Inc Stock (ONCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
| Aromando Andrew | Chief Business Officer |
Feb 11 '26 |
Buy |
0.86 |
29,600 |
25,418 |
55,100 |
| Andrews Patricia S | Director |
Feb 12 '26 |
Buy |
0.86 |
35,400 |
30,292 |
78,128 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):